{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:47:19Z","timestamp":1791380839022,"version":"4.3.3"},"reference-count":53,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Objectives\nTo pilot efficacy and safety data of quetiapine-XR monotherapy or adjunctive therapy to antidepressant(s) in the acute treatment of MDD with current generalized anxiety disorder (GAD).\nMethods\nThe Mini International Neuropsychiatric Interview was used to ascertain the diagnosis of DSM-IV Axis I disorders. Eligible patients were randomly assigned to quetiapine-XR or placebo for up to 8 weeks. Changes from baseline to endpoint in Hamilton Depression Rating Scale-17 items (HAMD-17), Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression-Severity (CGI-S), Quick Inventory of Depression Symptomatology-16 items Self-Report (QIDS-16-SR) total scores, and other outcome measures were analyzed with the last observation carried forward strategy and\/or mixed-effects modeling for repeated measures.\nResults\nOf the 34 patients screened, 23 patients were randomized to receive quetiapine-XR (n = 11) or placebo (n = 12), with 5 and 4 completing the study, respectively. The mean dose of quetiapine-XR was 154 \u00b1 91 mg\/d. The change from baseline to endpoint in the total scores of HAMD-17, HAM-A, QIDS-16-SR, and CGI-S were significant in the quetiapine-XR group, but only the change in HAM-A total score was significant in the placebo group. The differences in these changes between the two groups were only significant in CGI-S scores, with the rest of numerical larger in the quetiapine-XR group. The most common side effects from quetiapine-XR were dry mouth, somnolence\/sedation, and fatigue.\nConclusions\nIn this pilot study, quetiapine-XR was numerically superior to placebo in reducing depressive and anxiety symptoms in patients with MDD and current GAD. Large sample studies are warranted to support or refute these preliminary findings.<\/jats:p>","DOI":"10.64719\/pb.4339","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"8-23","source":"Crossref","is-referenced-by-count":2,"title":["A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder"],"prefix":"10.64719","volume":"46","author":[{"given":"Ranran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renrong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Ganocy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Gili M, Garc\u00eda Toro M, Armengol S et al. Functional impairment in patients with major depressive disorder and comorbid anxiety disorder. Can J Psychiatry. 2013;58(12):679\u2013686.","DOI":"10.1177\/070674371305801205"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Mergl R, Seidscheck I, Allgaier AK et al. Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. Depress Anxiety. 2007;24(3):185\u2013195.","DOI":"10.1002\/da.20192"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA. 2003;289(23):3095\u20133105.","DOI":"10.1001\/jama.289.23.3095"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Gao K, Wang Z, Chen J et al. Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity. J Affect Disord. 2013;148(2-3):256\u2013264.","DOI":"10.1016\/j.jad.2012.12.004"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Cyranowski JM, Schott LL, Kravitz HM et al. Psychosocial features associated with lifetime comorbidity of major depression and anxiety disorders among a community sample of mid-life women: the SWAN mental health study. Depress Anxiety. 2012;29(12):1050\u20131057.","DOI":"10.1002\/da.21990"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Pfeiffer PN, Ganoczy D, Ilgen M et al. Comorbid anxiety as a suicide risk factor among depressed veterans. Depress Anxiety. 2009;26(8):752\u2013757.","DOI":"10.1002\/da.20583"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gao K, Ming R, Wang Z et al. Differential associations of the number of comorbid conditions and the severity of depression and anxiety with self-reported suicidal ideation and attempt in major depressive disorder and bipolar disorder. J Depression Anxiety. 2015;4(1):173.","DOI":"10.4172\/2167-1044.1000173"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Mittal D, Fortney JC, Pyne JM et al. Predictors of persistence of comorbid generalized anxiety disorder among veterans with major depressive disorder. J Clin Psychiatry. 2011;72(11):1445\u20131451.","DOI":"10.4088\/JCP.10m05981blu"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Bet PM, Hugtenburg JG, Penninx BW et al. Treatment inadequacy in primary and specialized care patients with depressive and\/or anxiety disorders. Psychiatry Res. 2013;210(2):594\u2013600.","DOI":"10.1016\/j.psychres.2013.06.023"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Boschloo L, Vogelzangs N, van den Brink W et al. Depressive and anxiety disorders predicting first incidence of alcohol use disorders: results of the Netherlands Study of Depression and Anxiety (NESDA) J Clin Psychiatry. 2013;74(12):1233\u20131240.","DOI":"10.4088\/JCP.12m08159"},{"key":"ref11","unstructured":"Angst J. Depression and anxiety: implications for nosology, course, and treatment. J Clin Psychiatry. 1997;58(Suppl. 8):3\u20135."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Reich J, Warshaw M, Peterson LG et al. Comorbidity of panic and major depressive disorder. J Psychiatr Res. 1993;27(Suppl. 1):23\u201333.","DOI":"10.1016\/0022-3956(93)90015-T"},{"key":"ref13","unstructured":"Economic Working Group Advisory Board. Undertreatment of depression and comorbid anxiety translates into costly mismanagement of resources and poor patient outcomes. Manag Care. 2005;14(7 Suppl.):1\u201312."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Anderson IM, Ferrier IN, Baldwin RC et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343\u2013396.","DOI":"10.1177\/0269881107088441"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Brunette MF, Noordsy DL, Xie H et al. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54(10):1395\u20131401.","DOI":"10.1176\/appi.ps.54.10.1395"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Berger A, Edelsberg J, Treglia M et al. Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study. BMC Psychiatry. 2012;12:177.","DOI":"10.1186\/1471-244X-12-177"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Souery D, Oswald P, Massat I et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062\u20131070.","DOI":"10.4088\/JCP.v68n0713"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Wu Z, Chen J, Yuan C et al. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. J Affect Disord. 2013;150(3):834\u2013839.","DOI":"10.1016\/j.jad.2013.03.012"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lee TS, Nkouibert Assam P, Gersing KR et al. The effectiveness of antidepressant monotherapy in a naturalistic outpatient setting. Prim Care Companion CNS Disord. 2012;14(5)","DOI":"10.4088\/PCC.12m01364"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Shelton RC, Hollon SD, Wisniewski SR et al. Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. CNS Spectr. 2009;14(9):487\u2013498.","DOI":"10.1017\/S1092852900023555"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry. 2001;62(7):523\u2013529.","DOI":"10.4088\/JCP.v62n07a04"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Suppes T, Datto C, Minkwitz M et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1-2):106\u2013115.","DOI":"10.1016\/j.jad.2009.10.007"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sheehan DV, Harnett-Sheehan K, Hidalgo RB et al. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord. 2013;145(1):83\u201394.","DOI":"10.1016\/j.jad.2012.07.016"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Gao K, Wu R, Kemp DE et al. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial. J Clin Psychiatry. 2014;75(10):1062\u20131068.","DOI":"10.4088\/JCP.13m08847"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Gao K, Muzina D, Gajwani P et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67(9):1327\u20131340.","DOI":"10.4088\/JCP.v67n0902"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother. 2009;9(8):1147\u20131158.","DOI":"10.1586\/ern.09.37"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(2):103\u2013120.","DOI":"10.2165\/00023210-200923020-00002"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Sheehan DV, Sveds\u00e4ter H, Locklear JC et al. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord. 2013;151(3):906\u2013913.","DOI":"10.1016\/j.jad.2013.07.037"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Endicott J, Sveds\u00e4ter H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2012;8:301\u2013311.","DOI":"10.2147\/NDT.S32320"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Montgomery SA, Altamura AC, Katila H et al. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels. Int Clin Psychopharmacol. 2014;29(2):93\u2013105.","DOI":"10.1097\/YIC.0000000000000007"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Katila H, Mezhebovsky I, Mulroy A et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013;21(8):769\u2013784.","DOI":"10.1016\/j.jagp.2013.01.010"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Baune BT. New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. Neuropsychiatr Dis Treat. 2008;24(6):1181\u20131191.","DOI":"10.2147\/NDT.S3238"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Gao K, Verduin ML, Kemp DE et al. Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trials. J Clin Psychiatry. 2008;69(7):1057\u20131063.","DOI":"10.4088\/JCP.v69n0703"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573\u2013583.","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Endicott J, Nee J, Harrison W et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321\u2013326.","DOI":"10.1037\/t49981-000"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Shear MK, Rucci P, Williams J et al. Reliability and validity of the Panic Disorder Severity Scale: replication and extension. J Psychiatr Res. 2001;35(5):293\u2013296.","DOI":"10.1016\/S0022-3956(01)00028-0"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;((Suppl. 212)):11\u201319.","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u2013676.","DOI":"10.1192\/bjp.154.5.672"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Wisniewski SR, Rush AJ, Balasubramani GK et al. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12(2):71\u201379.","DOI":"10.1097\/00131746-200603000-00002"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Weisler R, McIntyre RS. The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. Expert Rev Neurother. 2013;13(11):1161\u20131182.","DOI":"10.1586\/14737175.2013.846520"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Maneeton N, Maneeton B, Srisurapanont M et al. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012;12:160.","DOI":"10.1186\/1471-244X-12-160"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Wang G, McIntyre A, Earley WR et al. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:201\u2013216.","DOI":"10.2147\/NDT.S50248"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Weisler R, Joyce M, McGill L et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14(6):299\u2013313.","DOI":"10.1017\/S1092852900020307"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Cutler AJ, Montgomery SA, Feifel D et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009;70(4):526\u2013539.","DOI":"10.4088\/JCP.08m04592"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Bauer M, El-Khalili N, Datto C et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010;127(1-3):19\u201330.","DOI":"10.1016\/j.jad.2010.08.032"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Bortnick B, El-Khalili N, Banov M et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011;128(1-2):83\u201394.","DOI":"10.1016\/j.jad.2010.06.031"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Bandelow B, Chouinard G, Bobes J et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010;13(3):305\u2013320.","DOI":"10.1017\/S1461145709990423"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Khan A, Joyce M, Atkinson S et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31(4):418\u2013428.","DOI":"10.1097\/JCP.0b013e318224864d"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Merideth C, Cutler AJ, She F et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012;27(1):40\u201354.","DOI":"10.1097\/YIC.0b013e32834d9f49"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Thase ME, Demyttenaere K, Earley WR et al. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574\u2013586.","DOI":"10.1002\/da.21970"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Bandelow B, Bauer M, Vieta E et al. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry. 2014;15(2):155\u2013166.","DOI":"10.3109\/15622975.2013.842654"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Gao K, Ganocy SJ, Gajwani P et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008;69(2):302\u2013309.","DOI":"10.4088\/JCP.v69n0217"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Gao K, Kemp DE, Fein E et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011;72(8):1063\u20131071.","DOI":"10.4088\/JCP.09r05535gre"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:25:37Z","timestamp":1791314737000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/a-randomized-placebo-controlled-pilot-study-of-quetiapine-xr-monotherapy-or-adjunctive-therapy-to-antidepressant-in-acute-major-depressive-disorder-with-current-generalized-anxiety-disorder\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4339","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}